PT3213750T - Combinação de dois antivirais para o tratamento da hepatite c - Google Patents

Combinação de dois antivirais para o tratamento da hepatite c

Info

Publication number
PT3213750T
PT3213750T PT171652076T PT17165207T PT3213750T PT 3213750 T PT3213750 T PT 3213750T PT 171652076 T PT171652076 T PT 171652076T PT 17165207 T PT17165207 T PT 17165207T PT 3213750 T PT3213750 T PT 3213750T
Authority
PT
Portugal
Prior art keywords
antivirals
combination
treating hepatitis
hepatitis
treating
Prior art date
Application number
PT171652076T
Other languages
English (en)
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3213750(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PT3213750T publication Critical patent/PT3213750T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT171652076T 2013-03-14 2014-03-14 Combinação de dois antivirais para o tratamento da hepatite c PT3213750T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361783376P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PT3213750T true PT3213750T (pt) 2020-10-19

Family

ID=50588882

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171652076T PT3213750T (pt) 2013-03-14 2014-03-14 Combinação de dois antivirais para o tratamento da hepatite c
PT147199772T PT2968301T (pt) 2013-03-14 2014-03-14 Combinação de dois antivirais para tratamento de hepatite c

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT147199772T PT2968301T (pt) 2013-03-14 2014-03-14 Combinação de dois antivirais para tratamento de hepatite c

Country Status (26)

Country Link
US (1) US20140275099A1 (pt)
EP (3) EP3766495A1 (pt)
JP (4) JP6441303B2 (pt)
KR (2) KR20210013344A (pt)
CN (2) CN105073113B (pt)
AU (2) AU2014239563B2 (pt)
BR (1) BR112015023017B1 (pt)
CA (1) CA2901810C (pt)
CY (2) CY1119025T1 (pt)
DK (2) DK2968301T3 (pt)
EA (2) EA201991174A1 (pt)
ES (2) ES2824473T3 (pt)
HK (2) HK1244668A1 (pt)
HR (2) HRP20171036T1 (pt)
HU (2) HUE052113T2 (pt)
IL (1) IL240419B (pt)
LT (2) LT3213750T (pt)
MX (2) MX362616B (pt)
NZ (2) NZ631155A (pt)
PL (2) PL2968301T3 (pt)
PT (2) PT3213750T (pt)
RS (2) RS56202B1 (pt)
SG (2) SG11201507364SA (pt)
SI (2) SI2968301T1 (pt)
TW (2) TWI642436B (pt)
WO (1) WO2014152514A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20140275099A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Methods for treating hcv
JP2016523924A (ja) * 2013-07-02 2016-08-12 アッヴィ・インコーポレイテッド Ｈｃｖの治療方法
CA2925328A1 (en) * 2013-10-25 2015-04-30 Abbvie, Inc. Methods for treating hcv
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
EP3125889A1 (en) * 2014-04-02 2017-02-08 AbbVie Inc. Methods for treating hcv
CA2943054A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US20160375087A1 (en) * 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CA2991417A1 (en) * 2015-07-08 2017-01-12 Abbvie Inc. Methods for treating hcv
RU2018105849A (ru) * 2015-07-17 2019-08-19 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20180085330A1 (en) * 2016-09-23 2018-03-29 Abbvie Inc. Dose Adjustment
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
TW202012001A (zh) * 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
US20210386735A1 (en) 2018-11-20 2021-12-16 Abbvie Inc. Methods of Treating Acute HCV
KR102077833B1 (ko) 2018-12-10 2020-02-14 류형준 기능성 식품조성물
CN111688355B (zh) 2019-03-15 2022-04-12 精工爱普生株式会社 液体吸收体、液体吸收器以及液体喷出装置
KR20210150501A (ko) * 2019-04-08 2021-12-10 애브비 인코포레이티드 Hcv를 치료하기 위한 고체 약제학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2012040167A1 (en) * 2010-09-21 2012-03-29 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived hcv serine protease inhibitors
US8330139B2 (en) 2011-03-25 2012-12-11 Micron Technology, Inc. Multi-level memory cell
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c
US20140275099A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Methods for treating hcv

Also Published As

Publication number Publication date
SG11201507364SA (en) 2015-10-29
MX362616B (es) 2019-01-28
TWI642436B (zh) 2018-12-01
KR20210013344A (ko) 2021-02-03
CA2901810A1 (en) 2014-09-25
EA201991174A1 (ru) 2020-01-31
RS60881B1 (sr) 2020-11-30
RS56202B1 (sr) 2017-11-30
WO2014152514A1 (en) 2014-09-25
PT2968301T (pt) 2017-07-17
AU2016202823B2 (en) 2017-11-23
ES2624980T3 (es) 2017-07-18
AU2014239563B2 (en) 2016-05-05
EP2968301B1 (en) 2017-04-19
HUE052113T2 (hu) 2021-04-28
TWI686196B (zh) 2020-03-01
DK3213750T3 (da) 2020-10-19
IL240419B (en) 2019-03-31
LT2968301T (lt) 2017-05-25
HK1223817A1 (zh) 2017-08-11
AU2016202823A1 (en) 2016-05-19
EA201591702A1 (ru) 2016-09-30
KR20150129032A (ko) 2015-11-18
CY1123387T1 (el) 2021-12-31
CN105073113B (zh) 2018-01-02
HRP20201575T1 (hr) 2020-12-11
SG10201708306WA (en) 2017-11-29
NZ631155A (en) 2016-05-27
JP2019048868A (ja) 2019-03-28
CA2901810C (en) 2019-01-08
HRP20171036T1 (hr) 2017-10-06
EP3213750B1 (en) 2020-08-12
LT3213750T (lt) 2020-10-26
PL3213750T3 (pl) 2020-12-14
EP3213750A1 (en) 2017-09-06
CN105073113A (zh) 2015-11-18
JP2021130720A (ja) 2021-09-09
ES2824473T3 (es) 2021-05-12
AU2014239563A1 (en) 2015-08-27
SI2968301T1 (sl) 2017-07-31
HK1244668A1 (zh) 2018-08-17
JP2020037589A (ja) 2020-03-12
CY1119025T1 (el) 2018-01-10
BR112015023017B1 (pt) 2022-08-30
JP2016513695A (ja) 2016-05-16
CN108159393A (zh) 2018-06-15
US20140275099A1 (en) 2014-09-18
JP6441303B2 (ja) 2018-12-19
TW201834656A (zh) 2018-10-01
JP6621902B2 (ja) 2019-12-18
EA033257B1 (ru) 2019-09-30
MX2015012538A (es) 2016-02-10
EP3766495A1 (en) 2021-01-20
IL240419A0 (en) 2015-09-24
SI3213750T1 (sl) 2020-11-30
BR112015023017A2 (pt) 2017-07-18
NZ719137A (en) 2017-11-24
HUE033010T2 (en) 2017-11-28
KR102210935B1 (ko) 2021-02-02
MX2020005054A (es) 2020-08-20
EP2968301A1 (en) 2016-01-20
TW201511759A (zh) 2015-04-01
DK2968301T3 (en) 2017-07-24
PL2968301T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
HK1223817A1 (zh) 用於治療丙型肝炎的兩種抗病毒劑的組合
IL278912A (en) Improved preparations for the treatment of muscular dystrophy
HK1213886A1 (zh) 用於治療心血管疾病的 -哌啶- -基苯甲酰胺衍生物
HUE050485T2 (hu) Tauopathia kezelési módszerei
EP2968273A4 (en) METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES
HK1209319A1 (en) Methods for treating hepatitis c
HK1209320A1 (en) Methods for treating hepatitis c
GB201308466D0 (en) Improved process for treatment of minewater
IL241096A0 (en) Treatment methods
GB201322764D0 (en) Treating places
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment